These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31215755)

  • 1. Safety, Tolerability, and Pharmacokinetics of the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor Verubecestat (MK-8931) in Healthy Elderly Male and Female Subjects.
    Forman M; Palcza J; Tseng J; Stone JA; Walker B; Swearingen D; Troyer MD; Dockendorf MF
    Clin Transl Sci; 2019 Sep; 12(5):545-555. PubMed ID: 31215755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study.
    Chris Min K; Dockendorf MF; Palcza J; Tseng J; Ma L; Stone JA; Kleijn HJ; Hodsman P; Masuo K; Tanen M; Troyer MD; van Vugt M; Forman MS
    Clin Pharmacol Ther; 2019 May; 105(5):1234-1243. PubMed ID: 30347431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.
    Egan MF; Kost J; Tariot PN; Aisen PS; Cummings JL; Vellas B; Sur C; Mukai Y; Voss T; Furtek C; Mahoney E; Harper Mozley L; Vandenberghe R; Mo Y; Michelson D
    N Engl J Med; 2018 May; 378(18):1691-1703. PubMed ID: 29719179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
    Kennedy ME; Stamford AW; Chen X; Cox K; Cumming JN; Dockendorf MF; Egan M; Ereshefsky L; Hodgson RA; Hyde LA; Jhee S; Kleijn HJ; Kuvelkar R; Li W; Mattson BA; Mei H; Palcza J; Scott JD; Tanen M; Troyer MD; Tseng JL; Stone JA; Parker EM; Forman MS
    Sci Transl Med; 2016 Nov; 8(363):363ra150. PubMed ID: 27807285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification and pharmacokinetic property of verubecestat an BACE1 inhibitor in rat plasma.
    Wang Q; Wang H; Zhong Y; Mei Y
    Biomed Chromatogr; 2020 Feb; 34(2):e4715. PubMed ID: 31633829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease.
    Doggrell SA
    Expert Opin Pharmacother; 2019 Dec; 20(17):2095-2099. PubMed ID: 31423903
    [No Abstract]   [Full Text] [Related]  

  • 7. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.
    Egan MF; Mukai Y; Voss T; Kost J; Stone J; Furtek C; Mahoney E; Cummings JL; Tariot PN; Aisen PS; Vellas B; Lines C; Michelson D
    Alzheimers Res Ther; 2019 Aug; 11(1):68. PubMed ID: 31387606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.
    Sur C; Kost J; Scott D; Adamczuk K; Fox NC; Cummings JL; Tariot PN; Aisen PS; Vellas B; Voss T; Mahoney E; Mukai Y; Kennedy ME; Lines C; Michelson D; Egan MF
    Brain; 2020 Dec; 143(12):3816-3826. PubMed ID: 33253354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of intermolecular interactions and stability of verubecestat in the active site of BACE1: Development of first model from QM/MM-based charge density and MD analysis.
    Saravanan K; Sivanandam M; Hunday G; Mathiyalagan L; Kumaradhas P
    J Biomol Struct Dyn; 2019 Jun; 37(9):2339-2354. PubMed ID: 30044206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BACE inhibitor bust in Alzheimer trial.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(3):155. PubMed ID: 28248932
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease.
    Thaisrivongs DA; Miller SP; Molinaro C; Chen Q; Song ZJ; Tan L; Chen L; Chen W; Lekhal A; Pulicare SK; Xu Y
    Org Lett; 2016 Nov; 18(22):5780-5783. PubMed ID: 27934506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.
    Qiu R; Ahn JE; Alexander R; Brodney MA; He P; Leurent C; Mancuso J; Margolin RA; Tankisheva E; Chen D
    J Alzheimers Dis; 2019; 71(2):581-595. PubMed ID: 31424395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931).
    Thaisrivongs DA; Morris WJ; Tan L; Song ZJ; Lyons TW; Waldman JH; Naber JR; Chen W; Chen L; Zhang B; Yang J
    Org Lett; 2018 Mar; 20(6):1568-1571. PubMed ID: 29481097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease.
    Scott JD; Li SW; Brunskill AP; Chen X; Cox K; Cumming JN; Forman M; Gilbert EJ; Hodgson RA; Hyde LA; Jiang Q; Iserloh U; Kazakevich I; Kuvelkar R; Mei H; Meredith J; Misiaszek J; Orth P; Rossiter LM; Slater M; Stone J; Strickland CO; Voigt JH; Wang G; Wang H; Wu Y; Greenlee WJ; Parker EM; Kennedy ME; Stamford AW
    J Med Chem; 2016 Dec; 59(23):10435-10450. PubMed ID: 27933948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacodynamic analysis of plasma Aβ40 and Aβ42 following single oral doses of the BACE1 inhibitor AZD3839 to healthy volunteers.
    Quartino A; Huledal G; Sparve E; Lüttgen M; Bueters T; Karlsson P; Olsson T; Paraskos J; Maltby J; Claeson-Bohnstedt K; Lee CM; Alexander R; Fälting J; Paulsson B
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):396-405. PubMed ID: 27129013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
    Naushad M; Durairajan SSK; Bera AK; Senapati S; Li M
    Planta Med; 2019 Nov; 85(17):1316-1325. PubMed ID: 31618777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2,2,2-Trifluoroethyl-thiadiazines: a patent evaluation of WO2016023927.
    Dotsenko VV; Chigorina EA; Krivokolysko SG
    Expert Opin Ther Pat; 2016 Dec; 26(12):1371-1376. PubMed ID: 27785946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective BACE1 inhibitor VIa reduces amyloid-β production in cell and mouse models of Alzheimer's disease.
    Cheng X; Zhou Y; Gu W; Wu J; Nie A; Cheng J; Zhou J; Zhou W; Zhang Y
    J Alzheimers Dis; 2013; 37(4):823-34. PubMed ID: 23948917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.